Suppr超能文献

中性粒细胞与淋巴细胞比值和血清糖类抗原19-9联合检测对胰头癌患者的预后影响

Prognostic impact of the combination of the neutrophil-to-lymphocyte ratio and serum carbohydrate antigen 19-9 in patients with pancreas head cancer.

作者信息

Kim Wan-Joon, Lim Tae-Wan, Park Pyoung-Jae, Choi Sae-Byeol, Kim Wan-Bae

机构信息

Division of Hepatobiliary Pancreas Surgery, Department of Surgery, Korea University Guro Hospital, Korea University Medical College, Seoul, Korea.

Division of Transplantation Vascular Surgery, Department of Surgery, Korea University Guro Hospital, Korea University Medical College, Seoul, Korea.

出版信息

ANZ J Surg. 2019 Jul;89(7-8):E302-E307. doi: 10.1111/ans.15029. Epub 2019 Mar 20.

Abstract

BACKGROUND

This study aimed to evaluate the clinical value of the combination of a traditional prognostic factor with a systemic inflammation-based prognostic factor in patients undergoing curative resection for pancreas head cancer diagnosed as pancreatic ductal adenocarcinoma.

METHODS

From January 2005 to December 2015, 198 patients were enrolled. Various clinicopathological factors potentially associated with survival and recurrence were evaluated in this study.

RESULTS

The selected cut-off values for the test prognostic factors with sufficient sensitivity and specificity were 2.8 for the neutrophil-to-lymphocyte ratio (NLR) and 70 U/mL for serum carbohydrate antigen 19-9 (CA19-9). Kaplan-Meier survival analysis demonstrated that the 5-year survival rate in patients with a high NLR and CA19-9 was 21.8% compared with 79.8% for patients with a low NLR and CA19-9. The 5-year disease-free survival rate in patients with a high NLR and CA19-9 was 0% compared with 33.9% for patients with a low NLR and CA19-9. Patients with high NLRs and high CA19-9 were more likely to have an early recurrence and multiple relapse patterns.

CONCLUSION

Preoperative NLR and serum CA19-9 offer significant prognostic information for survival following curative resection of pancreas head cancer diagnosed as pancreatic ductal adenocarcinoma.

摘要

背景

本研究旨在评估传统预后因素与基于全身炎症的预后因素相结合,在接受根治性切除的胰腺导管腺癌诊断为胰头癌患者中的临床价值。

方法

2005年1月至2015年12月,共纳入198例患者。本研究评估了各种可能与生存和复发相关的临床病理因素。

结果

具有足够敏感性和特异性的测试预后因素的选定临界值为中性粒细胞与淋巴细胞比值(NLR)为2.8,血清糖类抗原19-9(CA19-9)为70 U/mL。Kaplan-Meier生存分析表明,高NLR和CA19-9患者的5年生存率为21.8%,而低NLR和CA19-9患者为79.8%。高NLR和CA19-9患者的5年无病生存率为0%,而低NLR和CA19-9患者为33.9%。高NLR和高CA19-9的患者更有可能早期复发和出现多发复发模式。

结论

术前NLR和血清CA19-9为诊断为胰腺导管腺癌的胰头癌根治性切除后的生存提供了重要的预后信息。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验